GlassScriptPhysician profile
Ibad U Ansari
NPI 1245219997
$4,388.62
in general payments reported to CMS, 2019-2025
34 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $187 · 2021: $146 · 2022: $878 · 2023: $1,159 · 2024: $529 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $586.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $510.16 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $495.03 | 2019-2025 | |
| Amgen INC. | $425.31 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $380.78 | 2022-2024 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $340.44 | 2019-2023 | Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $226.48 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $207.77 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $157.20 | 2022-2023 | Verquvo |
| Penumbra, INC. | $106.67 | 2019 | |
| Shockwave Medical, INC | $83.53 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $76.21 | 2019-2023 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.52 | 2023 | Lifevest |
| Abbott Laboratories | $71.28 | 2022-2025 | Mitraclip, Perclose Prostyle |
| Boston Scientific Corporation | $60.94 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.58 | 2019 | |
| Alnylam Pharmaceuticals INC. | $54.07 | 2022-2023 | Onpattro |
| Cvrx, INC. | $50.81 | 2023 | Barostim Neo System |
| Astellas Pharma US INC | $45.85 | 2019 | |
| Abiomed | $43.68 | 2022 | |
| Novo Nordisk INC | $42.38 | 2019-2023 | Ozempic |
| Kestra Medical Technology Services, INC. | $38.59 | 2023-2025 | Assure Wcd |
| Teleflex LLC | $36.28 | 2022-2025 | Trapliner |
| Gilead Sciences, INC. | $34.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.17 | 2019-2022 | |
| Lantheus Medical Imaging, INC. | $19.69 | 2019 | |
| Terumo Medical Corporation | $18.84 | 2023 | Glidewire |
| Recor Medical INC | $17.89 | 2024 | Paradise Renal Denervation System |
| Kiniksa Pharmaceuticals, LTD. | $16.43 | 2023 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $15.55 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $15.33 | 2024 | Arcalyst |
| Chiesi USA, INC. | $15.26 | 2025 | Kengreal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.19 | 2019 | |
| Medtronic Vascular, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibad Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.